Onkologie. 2012:6(1):24-27

Targeted therapy in locally advanced gastric carcinoma - new trends in treatment

Andrea Jurečková, Michaela Všianská
Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

This article is aimed to summarize new targeted therapy used for treatment of advanced cancer of stomach and gastroesophageal junction.

Their efficacy is being tested in numerous clinical trials worldwide. Recent findings have suggested that this type of malignancy

is considered as a group of heterogenous tumors that differ in the expression of cell-signalling molecules. Toxicities of new targeted

therapy do not overlap those of cytotoxic agents and their effectivity was approved in other types of tumors.

Keywords: advanced gastric cancer, targeted therapy, trastuzumab, bevacizumab, lapatinib

Published: February 29, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jurečková A, Všianská M. Targeted therapy in locally advanced gastric carcinoma - new trends in treatment. Onkologie. 2012;6(1):24-27.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. De Vita F, Giuliani F, Silvestris N, et al. Human epidermal gowth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treatment Reviews 36S3 (2010).
    2. Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-9. A meta-analysis that showed the benefit of chemotherapy for patients with advanced gastric cancer. Go to original source... Go to PubMed...
    3. Meza-Junco J, Au HJ, Sawyer MB. Trastuzumab for gastric cancer. Expert opinion Biol.Therapy 2009; 9(12): 1543-1551. Go to original source...
    4. Rose JS, Bekaii-Saab TS. New developments in the treatment of metastatic gastrin cancer: focus on trastuzumab. Onco Targets and Therapy 2011; 4: 21-26. Go to original source...
    5. Van Cutsen E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a Report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997. Go to original source... Go to PubMed...
    6. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a Phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007; 25: 3210-3216. Go to original source... Go to PubMed...
    7. Bouche´ O, Raoul JL, Bonnetain F, et al. Randomized multicenter Phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Fe´ de´ ration Francophone de Cance´ rologie Digestive Group Study-FFCD 9803. J Clin Oncol 2004; 22: 4319-4328. Go to original source... Go to PubMed...
    8. Moehler M, Eimermacher A, Siebler J, et al. Randomized Phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) versus 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 2005; 92: 2122-2128. Go to original source... Go to PubMed...
    9. Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol 2010; 32: 57-65. Go to original source...
    10. Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy in firstline human epidermal growth factor receptor 2-positive advanced gastric cancer. J Clin Oncol (Meeting Abstracts) 2009; 27(15S): LBA4509. Go to original source...
    11. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805. Go to original source... Go to PubMed...
    12. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007; 59: 795-805. Go to original source... Go to PubMed...
    13. Kim SY, Kim HP, Kim YJ, et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 2008; 32: 89-95. Go to original source...
    14. Cortés-Funes H, Rivera F, Alés I, et al. Phase II of trastuzumab and cisplatin in patients with advanced gastric cancer with HER2/neu overexpression/amplification. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25(18s): abstract 4613. Go to original source...
    15. Chan JA, Blazskowsky LS, Enzinger PC. A multicenter phase II trial of single-agent cetuximab in advanced gastric and esophageal adenocarcinoma, Am J Oncol 2011; 22(6): 1367-1373. Epub 2011 Jan 7. Go to original source... Go to PubMed...
    16. Erbitux in combination with Xeloda and cisplatin in advanced esophago-gastric cancer, Multicenter, open label, randomized controlled study (EXPAND), Merck Serono.
    17. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24: 5201-5206. Go to original source... Go to PubMed...
    18. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study, J Clin Oncol 2011; 29: 3968-3976. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.